Effect of Concurrent Metformin on Adherence to and Persistence of Treatment With Second-Generation Antipsychotics in Nondiabetic Patients

<b>Conclusion:</b> The concurrent use of metformin with SGA drugs was associated with improved adherence and persistence to SGAs at both 180-and 365-day follow-up periods in adults with Medicaid and commercial insurance. Additionally, the observed improvement in SGA adherence among both early and delayed metformin initiators supports the effectiveness of metformin in enhancing adherence, whether used on a preventive basis or as a treatment for AIWG.